CD8A and neoplasm: Co-treatment with the Shh inhibitor sonidegib and anti–PD-L1 antibody blocks PD-L1 internalization and downstream signaling, reducing tumor progression and improving CD8+ T cell/Treg balance in preclinical models (47).